

The Canadian Nocturnal Oxygen (CANOX) trial

Submission date 16/09/2009	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 21/09/2009	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 23/04/2021	Condition category Respiratory	☐ Individual participant data

Plain English summary of protocol

06/06/2019: This record contains out of date information and will not be updated further. Please see <https://clinicaltrials.gov/ct2/show/NCT01044628> for the most up to date trial record.

Plain English summary not provided at time of registration.

Contact information

Type(s)

Scientific

Contact name

Dr Yves Lacasse

Contact details

Centre de recherche de l'Institut de cardiologie et de pneumologie de Québec (CRICPQ)

Hôpital Laval

2725 Chemin Ste-Foy

Québec

Canada

G1V 4G5

-

yves.lacasse@med.ulaval.ca

Additional identifiers

ClinicalTrials.gov (NCT)

NCT01044628

Protocol serial number

MCT-99512

Study information

Scientific Title

Multicentre randomised placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease

Acronym

CANOX, INOX

Study objectives

In patients with chronic obstructive pulmonary disease (COPD) not qualifying for long-term oxygenotherapy (LTOT) but who present significant nocturnal arterial oxygen desaturation, nocturnal oxygen (N-O2) provided for a period of 3 years is effective in decreasing mortality or delaying the requirement for LTOT, and is cost-effective and favorably compares to other medical interventions.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local medical ethics committee (Comité d'éthique de la recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec [Hôpital Laval]) pending approval; meeting planned for 03/11/2009

Primary study design

Interventional

Study design

Multicentre placebo-controlled randomised trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease (COPD)

Interventions

Nocturnal oxygen therapy (N-O2 study group): oxygen delivered overnight to allow the oxygen saturation to be greater than 90%

Placebo (control group): room air delivered by defective concentrator

The comparison will be double blind. COPD patients will be randomly assigned to 3 years of treatment with either home N-O2 or sham therapy with ambient air. Each patient will be followed-up for this period of 3 years, with regular visits (every 4 months) until one of the following events: the patient is prescribed LTOT or the patient dies.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

1. Mortality from all cause
2. Requirement for LTOT (composite outcome)

The usual socio-demographic and clinical characteristics will be obtained at baseline. Spirometry will be performed according to the American Thoracic Society requirements, lung volumes measurement by plethysmography, and carbon monoxide diffusion capacity measurement by the single-breath method (all measured at baseline, 12, 24 and 36 months). All arterial blood gases will be measured while breathing at room air (measured at baseline and every 4 months until 36 months). In case of death, the date at which the primary outcome is reached will be obtained directly from chart review, contact with the treating physician or on the basis of interviews with surviving relatives during the protocol-based home visits or telephone interviews.

Key secondary outcome(s)

1. Quality of life and utility measures, measured at baseline, 12 months, 24 months and 36 months
2. Costs from a societal perspective, measured through telephone contacts with patients every two months
3. Compliance with oxygen therapy, measured at 4, 8, 12, 16, 20, 24, 28, 32 and 36 months

Completion date

01/03/2014

Eligibility**Key inclusion criteria**

1. Patients with a diagnosis of COPD supported by a history of past or current smoking and obstructive disease: forced expiratory volume in one second (FEV1) less than 50% predicted, FEV1/forced vital capacity (FVC) less than 70% and a total lung capacity by body plethysmography greater than 80% predicted
2. Stable COPD at study entry for at least 6 weeks before enrolment in the trial, as demonstrated by:
 - 2.1. No acute exacerbation
 - 2.2. No change in medications
3. Non-smoking patients for at least 6 months before enrolment in the trial
4. Mild-to-moderate daytime hypoxaemia with a resting partial pressure of oxygen in arterial blood (PaO₂) (room air) in the range of 56 - 69 mmHg
5. Patients fulfilling the current definition of nocturnal oxygen desaturation, i.e., greater than or equal to 30% of the recording time with transcutaneous arterial oxygen saturation less than 90% on at least one of two consecutive recordings
6. Ability to give informed consent
7. Men and women aged over 40 years of age

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

243

Key exclusion criteria

1. Patients with severe hypoxaemia fulfilling the usual criteria for continuous oxygen (CONT-O2) at study entry: PaO2 less than or equal to 55 mmHg or PaO2 less than or equal to 59 mmHg with clinical evidence of at least one of the following:

1.1. Pulmonary hypertension

1.2. Right ventricular hypertrophy

1.3. Cor pulmonale

1.4. Haematocrit greater than or equal to 55%

2. Patients with proven sleep apnoea (defined by an apnoea/hypopnoea index of greater than or equal to 15 events/hour) or suspected sleep apnoea on oximetry tracings

3. Patients currently using nocturnal oxygen therapy (NO2)

4. Patients with known left heart or congenital heart diseases, interstitial lung diseases, bronchiectasis as the main cause of obstructive disease, lung carcinoma, severe obesity (body mass index greater than or equal to 40 kg/m²), or any other disease that could influence survival

Date of first enrolment

01/03/2010

Date of final enrolment

01/03/2014

Locations

Countries of recruitment

Canada

Study participating centre

Centre de recherche de l'Institut de cardiologie et de pneumologie de Québec (CRICPQ)

Québec

Canada

G1V 4G5

Sponsor information

Organisation

Laval Hospital (Hôpital Laval) (Canada)

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) (ref: MCT-99512)

Alternative Name(s)

Instituts de Recherche en Santé du Canada, The Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Canada

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		17/09/2020	23/04/2021	Yes	No
Protocol article	protocol	09/01/2017		Yes	No